# Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

> **NCT01578564** · PHASE1 · COMPLETED · sponsor: **Soricimed Biopharma Inc** · enrollment: 23 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** SOR-C13

## Key facts

- **NCT ID:** NCT01578564
- **Lead sponsor:** Soricimed Biopharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-07
- **Final completion:** 2016-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578564, "Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT01578564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*